Revance announced that it has achieved the key milestone of having distributed one million vials of Daxxify (daxibotulinumtoxinA-lanm) for aesthetics in the U.S. This achievement comes only three years after the product’s FDA approval and highlights the position Daxxify plays as the fastest-growing neurotoxin in the country. This frown line treatment is made without human or animal-based components. It has a unique clinical profile that combines a fast onset with the ability to smooth even the deepest lines and deliver long-lasting results. “Reaching the one million vial mark represents an important milestone in the advancement of aesthetic medicine and of Daxxify,” says Conor Gallagher Ph.D., chief scientific officer of Revance. “This achievement highlights the trust our provider partners place in our peptide formulated neurotoxin and reflects the value they place in innovation that translates into true clinical outcomes. We are encouraged by the growing body of real-world experience, and we are actively continuing to expand the science and data supporting Daxxify.”